53.00 +0.07 (0.13%)
Pre-Market: 6:34AM EDT
|Bid||52.40 x 3200|
|Ask||54.22 x 800|
|Day's Range||52.56 - 53.11|
|52 Week Range||51.77 - 82.15|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||2.00 (3.46%)|
|1y Target Est||73.04|
CVS Health will open "hundreds" of SmileDirectClub locations inside its stores this year. Called a SmileShop, customers can receive a 3D scan of their teeth that's used to create a pair of invisible braces. Walgreens is testing SmileDirectClub locations in four of its stores.
NEW ORLEANS, April 24, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
NEW YORK, NY / ACCESSWIRE / April 24, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
LOS ANGELES, CA / ACCESSWIRE / April 24, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 21, 2015 and February 20, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before April 26, 2019.
Temple officials said the Aetna deal will help the health system expand value-based purchasing programs and quality initiatives.
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmark initiated coverage of Colorado-based cannabis company Charlotte's Web Holdings Inc. with a buy rating and a $25 price target that is 25% above its current trading level. Analyst Mike Hickey listed a range of positives for the stock, including an early move advantage in the CBD market, a vertically integrated business model with a large 2018 hemp harves, and the rapid expansion of its retail network. "CWEB is a US market share leader and pure play in the CBD market, with an established brand, 4,000-plus domestic retail distribution locations and significant online sales," Hickey wrote in a note. The analyst also lauded the recent 2018 Farm bill, which legalized hemp, which he now expects will become a significant agricultural commodity. The company is expecting to benefit from the CBD market, which The Hemp Business Journal is expecting to become a nearly $7 billion market by 2023. Companies including CVS , Rite Aid and Walgreens have started selling CBD-infused products, although these are not yet allowed by the U.S. Food and Drug Administration. The FDA took over regulation of CBD from the DEA when hemp was legalized and it has said companies cannot add the substance to food or drinks for now. However, some companies have moved ahead anyway, as they are not expecting enforcement actions. Charlotte's Web shares have gained 81% in the year to date, while the S&P 500 has gained 11.9%.
WOONSOCKET, R.I., April 24, 2019 /PRNewswire/ -- As part of its commitment to helping build healthier communities, CVS Health (CVS) is reminding Americans to clean out their medicine cabinets and safely dispose of unused medication on National Prescription Drug Take-Back Day, this Saturday, April 27. According to the National Survey on Drug Use and Health, in-home medicine cabinets are often a source of diverted medications, and CVS Pharmacy recommends that patients dispose unused medicines promptly, safely, and securely.
NEW YORK, NY / ACCESSWIRE / April 24, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...
LOS ANGELES / ACCESSWIRE / April 23, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE: CVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between May 21, 2015 and February 20, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before April 26, 2019.
NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against CVS Health Corporation (''CVS'' or the ''Company'') (CVS) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-01725, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired CVS Health securities between May 21, 2015 and February 20, 2019, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
WOONSOCKET, R.I., April 23, 2019 /PRNewswire/ -- CVS Pharmacy, the retail division of CVS Health (CVS), announced today that it has completed the rollout of time delay safes in all of its 186 CVS Pharmacy locations in Alabama. The safes are anticipated to help prevent pharmacy robberies and the diversion of controlled substance narcotic medications by keeping them out of the hands of unauthorized individuals.
CVS Health (NYSE:CVS) is an organization that should do well in any part of the economic cycle, since we all need medicine and healthcare products from time to time. So on paper, CVS stock has similar characteristics to Home Depot (NYSE:HD) and Procter & Gamble (NYSE:PG).Source: Mike Mozart via FlickrBut unlike those latter names, CVS and other retail pharmacy stocks have not done well over the past few years. Since August 2015, CVS has dropped over 50%. Even worse, the owners of CVS stock have nothing on the horizon to cheer about, and CVS has tumbled 20% since January.Confronting retail pharmacy stocks, including CVS, is a double whammy of potentially crippling headwinds. First, the retail pharmacy giant must address political and public anger against rising healthcare costs. After embarrassing controversies such as the "pharma bro" scandal, the American electorate will make this a pivotal issue next year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 High-Yielding Dividend Stocks That Won't Wilt Not only that, but political momentum appears to be moving further against retail pharmacy stocks. That's troubling for the owners of CVS stock. Specifically, popular presidential candidates like Bernie Sanders have supported initiatives like the "Medicare for All Act." Rising stars like Democratic and economic firebrand Andrew Yang are guaranteed to make "Medicare for All" a political talking point.That is already a huge problem for retail pharmacy stocks. But the other dark cloud impacting CVS stock is competition. I'm not just talking about individual players in a hurting sector cutting each others' throats. Rather, I'm calling out the giant gorilla in the room: Amazon (NASDAQ:AMZN).I love Amazon because it's an unrivaled American success story. But let's also be honest: Amazon's success has come at the expense of other American businesses. Now that AMZN has its eyes on retail pharmacy, it's no wonder why CVS stock is so volatile. Threats Rattle CVS, But They Won't Be FatalNo matter how you look at it, CVS stock is incredibly risky. Unfortunately, recent developments have put more pressure on CVS. But as bad as things have gotten, the headwinds facing CVS stock are not completely devastating.While the political noose appears to be tightening its grip on CVS, this dynamic also offers opportunity. Sure, CVS and other pharmacy stocks probably won't benefit anymore from overpriced prescription medicine. However, if the Democrats take over the White House next year - and that's a real possibility - millions of underserved Americans will have access to quality healthcare insurance.These Democratic policies will cause many Americans who are buying drugs in foreign countries to obtain them in the U.S. instead.Earlier this year, NPR highlighted the case of Michelle Fenner. Doctors diagnosed her son with Type 1 diabetes almost a decade ago, meaning he requires daily insulin shots to live. Last year, a three-month supply of insulin rose to $3,700.In Tijuana, Mexico, however, Fenner only has to pay an amazingly low $600. Such extraordinary discounts have inspired up to 320,000 Americans to travel abroad for healthcare reasons each year. Therefore, cost-cutting measures may initially hurt the profit margins of retail pharmacy stocks. But at the same time, the retailers would also capture revenue that previously went to foreign countries.That's not all. According to Harvard Health Publishing, millions of Americans skimp on medication because of their exorbitant costs. Again, a cap on costs would initially hurt the profit margins of pharmaceutical retailers. But in the long run, pharmacy retailers will obtain revenue from new sources, boosting CVS stock. Amazon Can't Quite Disrupt CVSAs I mentioned earlier, disruptive competition presents a serious threat to CVS stock. Amazon succeeded in disrupting multiple retail segments. Therefore, it's only natural to assume that AMZN will also cripple CVS.However, pharmacy retail is unlike other retail categories because consumers often need their medication right way. For instance, if someone has an especially explosive case of diarrhea, he's not going to wait three to five business days for a treatment to be shipped to him. Instead, he needs relief right away.As a result, I think Amazon's overall impact on pharmacies will be similar to its impact on the home-improvement sector. Home Depot (NYSE:HD) must contend with competition from the e-commerce giant. However, traditional brick-and-mortar locations serve consumers looking for home-improvement products well. They get what they want, when they want it. That attribute is much more important for people who need drugs.Having said all that, I'm not entirely gung-ho on CVS stock. The underlying company has a huge debt load. Moreover, it has struggled to adapt to its industry's changing landscape.But it's also very possible that, in the wake of the decline of CVS stock, the bad news is already reflected in the shares. Once investors realize that the bad news isn't all that terrible, CVS could rally, at least for awhile.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post CVS Stock Isnat in as Much Trouble as You Might Think appeared first on InvestorPlace.
According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of Bristol-Myers Squibb Company (BMY) shares has declined to close to the 52-week low of $45.52, which is 30.4% off the 52-week high of $63.69. The company has a market cap of $74.38 billion.
NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
NEW ORLEANS, April 22, 2019 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
NEW YORK, April 22, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
Gilead Sciences Inc., CVS Health Corp, Macerich Co. and OPKO Health Inc. have declined to their respective three-year lows
Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included a leading airline and a pharmaceutical giant. And bearish calls included cruise line operators ...